產品詳情
簡單介紹：
Anti-PCTAIRE2抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-PCTAIRE2抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-PCTAIRE2
Cat. Number:
Anti-PCTAIRE2抗體KL-11574R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Cell cycle progression is controlled in part by a family of cyclin proteins and cyclin dependent kinases (Cdks). Cdk proteins work in concert with cyclins to phosphorylate key substrates involved in cell cycle progression. Another Anti-PCTAIRE2抗體family of proteins, Cdk inhibitors, also play a role in regulating the cell cycle by binding to cyclin-Cdk complexes and modulating their activity. Members of the Cdk family include Cdk2–Cdk8, PCTAIRE-1–3, PITALRE and PITSLRE. PCTAIRE-1, PCTAIRE-2 and PCTAIRE-3 comprise a subfamily of cdc2-related serine/threonine kinases. PCTAIRE-1, which is expressed primarily in mammalian brain, interacts with a variety of proteins and is thought to be part of a multiple signal transduction cascade. PCTAIRE-2, also expressed in brain, may be important in terminally differentiated neurons.
Also known as:
PCTAIRE-2; PCTAIRE-motif Anti-PCTAIRE2抗體protein kinase 2; PCTK2; Protein kinase cdc2-related PCTAIRE-2; Serine/threonine-protein kinase PCTAIRE-2; 6430598J10Rik; EC 2.7.1.37; MGC25109; CDK17_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Chicken, Dog, Cow, Rabbit, Sheep, shp.
●
Immunogen: KLH conjugated Anti-PCTAIRE2抗體synthetic peptide derived from human PCTAIRE2 (301-400aa).
●
Predicted Molecular Weight: 60kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-PCTAIRE2抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
